$GKOS

Gilliam Joseph E sold $10.8M of GKOS

Gilliam Joseph E (PRESIDENT & COO) sold 60,000 shares of GLAUKOS Corp (GKOS) at an average of $179.74 ($178.89–$180.49, $10.78M total) across 2 trades on 2026-08-11.

Original reporting
SEC EDGAR · Gilliam Joseph E
Published Aug 13, 2026, 11:57 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 11:59 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$GKOS
Neutral
medium confidence
Mentioned
$GKOS
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GKOSNeutralLow
01

Why it matters

The newest disclosed fact is the open-market sale of 60,000 shares on 2026-08-11 at $178.8900 to $180.4900, with holdings after the sale of 72,588 shares.

02

Market read

Traders may briefly reassess sentiment around GKOS due to insider selling, but there is no accompanying operational or financial catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, pre-planned personal needs, or option/RSU mechanics not captured here; traders should check for other recent insider activity and any concurrent company news.

Relevance 7/10Novelty 4/10Timing: filed 2026-08-13 after trades dated 2026-08-11

Background

The article is a SEC Form 4 insider transaction disclosure for GLAUKOS Corp (GKOS) by its President and COO.

Company-level read

Ticker impact

$GKOSNeutralMedium confidence
Context

Form 4 shows GKOS COO sold 60,000 shares in open-market transactions totaling about $10.78M at ~$179.74 average.

Expected impact

Likely limited, short-lived sentiment impact; follow-through depends on broader news flow.

Evidence & confidence

The filing is a primary-source Form 4 disclosure with transaction size and pricing, but it does not include new guidance, contracts, or regulatory/clinical catalysts.

Market effects

No clear sector read-through from a single insider sale without additional company-specific developments.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity or tax-related, especially since it is not stated as part of a 10b5-1 plan, so it may not signal deteriorating fundamentals.

Key entities

  • GLAUKOS Corp

    Company whose insider transaction is disclosed via Form 4.

  • Gilliam Joseph E

    President and COO who sold 60,000 shares in open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GKOSMedAI 8/10

Glaukos (GKOS) Q2 2026 Earnings Call Transcript

Glaukos (NYSE: GKOS) reported Q2 2026 net sales of $185.6 million, up 50% year over year. U.S. glaucoma sales were $118.5 million, and iDose TR revenue was about $74 million. The company raised full-year 2026 net sales guidance to $680 million to $700 million and iDose TR revenue guidance to $275 million to $280 million.

$GKOSHighAI 9/10

Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up

Glaukos (GKOS) reported Q2 2026 adjusted loss of 14 cents per share, better than the Zacks Consensus loss of 28 cents. Revenue rose to $185.6 million, up 50% year over year, beating the consensus by 24.1%. Management raised 2026 net sales guidance to $680 million to $700 million. Shares rose 9.8% in after-hours.

$GKOSMed

Glaukos Q2 Earnings Call Highlights

Glaukos (NYSE:GKOS) reported Q2 updates on iDose TR, including acceleration across Medicare Administrative Contractor regions and no material demand pull-forward from proposed LCDs. International glaucoma revenue rose to $36.6M (+17%); corneal health revenue rose 48% to $30.4M with ~$11M Epioxa. Gross margin was ~85%. Full-year targets: gross margin 84% to 86%, corneal health growth ~20%.

$GKOSMedAI 8/10

GLAUKOS Corp (GKOS): Results of Operations and Financial Condition

GLAUKOS Corp (GKOS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 gkos-ex99_2.htm EX-99.2 EX-99.2 Exhibit 99.2 JULY 29, 2026 GLAUKOS CORPORATION (NYSE: GKOS) SECOND QUARTER 2026 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designe

$GKOSMed

Midday Stock Roundup: Glaukos Rises

A midday roundup highlights multiple movers. V.F. Corp. (VFC) fell 17% to $15.24 after lower first-quarter revenue tied to weakness in Vans and CFO Paul Vogel leaving. Envista (NVST) rose 6.2% to $28.63 ahead of an Sept. 17 investor day. Glaukos (GKOS) gained 7.9% to $159.25 after completing patient enrollment in a 510(k) glaucoma study.